4month20On the day, the Boao Forum for Asia's International Health Industry Forum grandly opened at the Beijing Economic-Technological Development Area. This forum is a thematic session under the framework of the Boao Forum for Asia Global Health Forum, co-hosted by the Boao Forum for Asia and the People's Government of Beijing Municipality, and co-organized by the Global Health Forum Conference Organizing Committee and the Beijing Economic-Technological Development Area Management Committee.
As strategic partners of this forum, Frost & Sullivan and LeadLeo Research Institute, together with the Organizing Committee of the Boao Forum on Global Health, jointly released 'Research White Paper on the Global Pharmaceutical and Healthcare Industry Layout and Development Trends' and 'Outlook2030White Paper on the Development Prospect of China's Big Health IndustryCDMOResearch Report on the Current Industry Situation and Development Trends, and New Opportunities for the Modernization and Development of China's Traditional Chinese Medicine Industry with a Long-standing Heritage4This heavyweight white paper.
Yin Li, Secretary of the Beijing Municipal Party Committee, and Yin Yong, Mayor of Beijing, met with important guests attending the event respectively and participated in related forum activities. Zhou Xiaochuan, Vice Chairman of the Boao Forum for Asia, Chen Zhu, President of the Red Cross Society of China, Li Baodong, Secretary-General of the Boao Forum for Asia, Chen Fengfuzhen, Chairperson of the Global Health Forum, Shen Hongbing, Academician of the Chinese Academy of Engineering, Deputy Director of the National Disease Prevention and Control Administration, Director of the Chinese Center for Disease Control and Prevention, Sun Da, Secretary of the Party Committee and Vice President of the China Charity Federation, Yu Mengsun, Academician of the Chinese Academy of Engineering, Expert in Aerospace Medicine and Biomedical Engineering, Xu Jianguo, Academician of the Chinese Academy of Engineering, Dean of the Public Health and Health Research Institute at Nankai University, and Moin, Ambassador of Pakistan to China・Hak, Ojai, Director of the East Asia Office of the International Federation of Red Cross and Red Crescent Societies, Chang Qide, United Nations Resident Coordinator in China, and Alain from the Mériel Foundation in France・Mérye, Jiang Xiaosong, President of Japan's international healthcare organization, and Dr. Christoph Schaefer, Global Health Envoy of the German Embassy in China, among other Chinese and foreign guests, attended the forum.
The Health Industry International Forum, themed 'Global Health: Industrial Development and Sharing', has a total of1Opening Ceremony and General Meeting,8Arena Division Forum,6Release of the industry report and2The closed-door dialogue session will be followed by more than 20 important events, with representatives from politics, business, academia, media and other sectors scheduled500People and the World. The forum engaged in in-depth discussions on topics such as global eradication of poliomyelitis, cell and gene therapy, smart healthcare, innovative development of traditional medicine, addressing the challenge of antibiotic resistance, the development of the medical diagnostic product industry, nutrition and health, the new future of medical security, etc.
Frost & SullivanFrost & SullivanDr. Wang Xin, Global Partner and President of Greater China at Frost & Sullivan, was invited to participate in a closed-door dialogue meeting between the Economic Development Zone and entrepreneurs on the Health Industry International Forum of the Boao Forum for Asia. Kong Lei, Director of the Management Committee of Beijing Economic and Technological Development Area, and Liu Li, Deputy Director of the Management Committee, attended the meeting and introduced the overall situation of Beijing Economic and Technological Development Area to the guests present. Zhu Yougang, Secretary of the Party Committee and Chairman of Ping An Health Insurance, Zhang Songshan, Senior Manager of Central Government Affairs for Boston Scientific Greater China, Zhou Yuan, Head of Strategic Market Access for Stryker Medical China, Liu Chang, Vice President of Health Affairs and Market Access at Boehringer Ingelheim (China), Huang Bin, Chairman of AstraZeneca Pharmaceuticals China Limited, and Zhu Hailuan, Vice President of Sanofi Greater China, among other corporate representatives, also participated in the meeting.
The development prospects of China's healthcare industry are broad
At the meeting, Dr. Wang Xin first briefly analyzed the opportunities for the healthy development of healthcare in China. 'Data shows that the United StatesTop 20The average enterprise market value is about1,800billions of dollars, while ChinaTop 20The average enterprise market value is less than200billions of dollars, a huge gap. In addition, ChinaTop 20The total market value of the enterprise is less than4,000billion US dollars, lower than the market value of UnitedHealthcare, a US pharmaceutical giant. "Therefore, Dr. Wang Xin believes that Chinese pharmaceutical companies are still focusing on their home market, with enormous growth potential ahead. Leading enterprises urgently need to shine forth. In addition, multiple factors such as economic growth, policy support, technological progress, and capital assistance also favor the development of China's healthcare industry, which has broad development opportunities in the medium to long term.
The popular tracks are highly competitive, and the park urgently needs industrial positioning support.
Capital investment is an indispensable and important factor driving the growth of biopharmaceutical companies, and it is crucial for promoting research and development and accelerating business success in the life sciences industry. Although the Chinese pharmaceutical capital market has been enthusiastic in recent years, with the Hong Kong stock marketAWith the relaxation of the listing policy for pharmaceutical companies without revenue, the number of Chinese healthcare enterprises listed has gradually increased, alone2020,2021As high as181Chinese medical enterprises at homeAListed on the Hong Kong stock market, US stock market or NASDAQ. However, Dr. Wang Xin also mentioned that in fact, some biotech tracks are very crowded and have formed a red ocean competition, leading to fragmented sub-tracksBiotechPharmaceutical companies mainly face three major challenges: severe product homogenization, fierce price competition, and serious talent loss. "How does the park identify suitable development directions in these red oceans, make good industrial plans and investment promotion, and select high-quality enterprises to settle in the park? Every step is full of challenges and requires key support from professional institutions," said Dr. Wang Xin.
Accumulate knowledge and skills over time, deeply cultivate the industry, and build a leading investment and financing platform
Dr. Wang Xin said, This year marks the 50th anniversary of Frost & Sullivan's global establishment.62The anniversary is also the first time we have entered the Chinese market25As a global growth consulting firm, Frost & Sullivan has always been committed to helping businesses grow, marking the occasion with a special anniversary event. Deeply involved in global capital markets and corporate consulting services, we provide comprehensive investment and financing as well as various other professional consulting services for enterprises. We help clients accelerate their growth, assist them in achieving growth, technological innovation, and leading benchmarks within the industry. We have helped nearly a thousand companies successfully list on the Hong Kong and overseas stock exchanges, making us a leading enterprise in the field of investment strategy consulting in China. The big health industry is one of the core focus areas of Frost & Sullivan's research, and in recent years20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. 2014till2022In [year], Frost & Sullivan retained its leading position as the market research advisor with the largest share of the Chinese companies going public in Hong Kong and overseas, and is also an absolute leader in serving healthcare companies on their listing in Hong Kong; furthermore;2019year7Since the listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board-listed companies in the industry.
We provide all-round services with innovative concepts and models
In addition, according to its introduction, Frost & Sullivan is also actively applying the pioneering concept of 'Whole-Enterprise Investment Management (TIM,Total Investment Management)"New concepts, new models, Comprehensively provides investment management services for enterprises, including enterprise management, regulatory communication, industry development trend analysis, market and strategic planning, brand value empowerment, etc., and gives full play to 5R(in other wordsPRPublic Relations,IRInvestor RelationsGRgovernment relationsARAnalyst relationsVRValue relations Management advantages, helping enterprises position themselves and enhance value, telling the capital market story well, and achieving efficient communication with investment institutions, investors, industry-related parties, stakeholders, etc., make it one of the most powerful, professional, and influential comprehensive industry research institutions in the industry.
Professional content has gained wide recognition in the capital market
In recent years, Frost & Sullivan has continuously produced a large number of professional and accurate analyses and high-quality publications for various industries, which are widely recognized by regulatory authorities, investment and financing institutions, investors, enterprises, academic institutions, research institutions, professional service agencies, etc. Dr. Wang Xin specifically cited an example, 'Every year, Frost & Sullivan collaborates with Frost & Sullivan TradeGo (Shenzhen) Cloud Technology Co., Ltd., TradeGo, and LeadLeo Research Institute to author and publish Hong Kong stocks18ABiotech companies issue investment activity reports, Hong Kong stockSaaSIndustry Activity Report, China Property Management Industry Investment Activity Report, China Consumer Healthcare Series Report, China Specialized Hospital Services Series Report, Hong KongIPO listingMarket and Secondary Market White Paper awaiting, and plans for publication ASeries of Industry Analysis Reports on Stocks and Sci-tech Innovation Board Please stay tuned!”
Recommended Reading:
· Heavyweight!2022Hong Kong stocks for the yearSaaSThe "Industry Pulse Report" is now available!
Professional empowerment for the high-quality development of industrial parks
Based on its global brand heritage, strong professional expertise, and high service standards, Frost & Sullivan has unique advantages and has accumulated rich experience in the field of park planning and consulting. At the front end of planning and consulting services, Frost & Sullivan is a leader in industrial research and strategic thinking, using its powerful industrial analysis capabilities to assist in precise regional positioning. At the back end of planning and consulting services, Frost & Sullivan can also provide implementation and operational support, integrating internal and external resources to assist in planning implementation. In recent years, Frost & Sullivan has participated in numerous industrial sorting and planning consulting projects. In major urban agglomerations and economic hotspots in China, such as Shanghai, Nanjing, Suzhou, Guangzhou, Chongqing, Chengdu, Xi'an, etc., project practices are carried out.
Dr. Wang Xin said, "In the process of helping a large number of clients achieve their strategic goals at Frost & Sullivan, we have established close, efficient, and united cooperative relationships with many securities firms, investment banks, law firms, and other professional service institutions. We have created one-stop investment and financing solutions, working together to empower enterprise growth, industrial development, and economic takeoff. The results are evident. In the future, Frost & Sullivan also hopes to continue collaborating with core strategic partners such as LeadLeo and cloud technology, along with many professional institutions, to jointly build an ecological service system covering the entire lifecycle and industrial chain of enterprises. This will help biopharmaceutical companies achieve growth, provide planning consultations for the industrial layout of biopharmaceutical parks, and empower the transformation and upgrading of the biopharmaceutical industry!"
As strategic partners of this forum, Frost & Sullivan and LeadLeo Research Institute, together with the Organizing Committee of the Boao Forum on Global Health, jointly released 'Research White Paper on the Layout and Development Trends of the Global Pharmaceutical and Healthcare Industry' and 'Outlook2030White Paper on the Development Prospect of China's Big Health IndustryCDMO companyResearch Report on the Current Industry Situation and Development Trends, and New Opportunities for the Modernization and Development of China's Traditional Chinese Medicine Industry with a Long-standing Heritage4This heavyweight white paper. Dr. Wang Xin, Global Partner and President of Frost & Sullivan Greater China, Yang Xiaocheng, Partner and Managing Director of Frost & Sullivan Greater China, Guo Jing, Senior Consulting Director for the Healthcare Industry at Frost & Sullivan Greater China, and Li Zheng, Dean of LeadLeo Research Institute, attended the press conference and provided in-depth interpretations of the report. Professor Wang Yu, Expert Advisor to the Boao Forum for Asia's Global Health, Dr. Wu Zhisheng, Distinguished Researcher and Doctoral Supervisor at Beijing University of Chinese Medicine, also attended the report release ceremony.
Recommended Reading:
After the meeting, Li Baodong, Secretary-General of the Boao Forum for Asia, and his delegation visited Wallich Medical Equipment (China) Co., Ltd., a biopharmaceutical enterprise in Beijing Economic-Technological Development Area. Kong Lei, Director of the Management Committee of Beijing Economic-Technological Development Area, accompanied the visit. Dr. Wang Xin, Yang Xiaocheng, and relevant responsible persons from some participating enterprises also went along.
According to the relevant person in charge of the Economic Development Zone, biotechnology and the big health industry are one of the four leading industries of the zone. After long-term cultivation and accumulation, the Economic Development Zone has gathered various types of enterprises.3,500, including Bayer, Sanofi,GEValiant, AstraZeneca, and a group of companies from around the world500Strong enterprises. Listed companies22Home, ranking first in Beijing. A preliminary industrial development ecosystem with scale aggregation and a sound system has taken shape, with the industrial scale accounting for more than [X]% of Beijing's biomedicine industry for several consecutive years.40%In addition, with the upcoming implementation of the "Six Centers" by the National Medical Products Administration, the biotechnology and big health industries in the Economic Development Zone will also embrace new development opportunities. A relevant official from the Special Working Group on Biotechnology and Big Health Industries in the Economic Development Zone stated that efforts are being made to2025In [year], the scale of the biotechnology and big health industries in the Economic Development Zone was promoted to exceed a certain mark2,000100 million yuan.
The high-quality development of the global health industry is an important guarantee for enhancing people's well-being and a significant support for promoting economic development. The global health industry has entered an important period of opportunity and is becoming a new engine for the global economy's energy storage and growth momentum.
Dr. Wang Xin stated that the knowledge in the field of biotechnology is vast and ever-evolving, with new technologies and discoveries emerging daily. Human demand for health is endless, and biotechnology is crucial to the future of humanity. Frost & Sullivan will continue to support and assist biotech companies in their growth, helping them better engage in the relentless pursuit of life sciences, promoting the prosperous development of China's large health industry, and seeking well-being for all mankind.
